Cited by 4,262Protein Degradation and InhibitorsChromatin Remodeling and CancerEpigenetics and DNA Methylation

The DOI matches its Crossref record; 40 of the 42 references it cites were found in a registry or an index.

Selective inhibition of BET bromodomains

Open access

Filippakopoulos, Panagis, Qi, Jun, Picaud, Sarah, Shen, Yao, Smith, William B., Fedorov, Oleg, Morse, Elizabeth M., Keates, Tracey, Hickman, Tyler T., Felletar, Ildiko, Philpott, Martin, Munro, Shonagh, McKeown, Michael R., Wang, Yuchuan, Christie, Amanda L., West, Nathan, Cameron, Michael J., Schwartz, Brian, Heightman, Tom D., La Thangue, Nicholas, French, Christopher A., Wiest, Olaf, Kung, Andrew L., Knapp, Stefan, Bradner, James E.·2010·Nature

DOI 10.1038/nature09504PMC PMC3010259

Open this paper in CoChat — free account

Abstract

Epigenetic proteins are intently pursued targets in ligand discovery. So far, successful efforts have been limited to chromatin modifying enzymes, or so-called epigenetic 'writers' and 'erasers'. Potent inhibitors of histone binding modules have not yet been described. Here we report a cell-permeable small molecule (JQ1) that binds competitively to acetyl-lysine recognition motifs, or bromodomains. High potency and specificity towards a subset of human bromodomains is explained by co-crystal structures with bromodomain and extra-terminal (BET) family member BRD4, revealing excellent shape complementarity with the acetyl-lysine binding cavity. Recurrent translocation of BRD4 is observed in a genetically-defined, incurable subtype of human squamous carcinoma. Competitive binding by JQ1 displaces the BRD4 fusion oncoprotein from chromatin, prompting squamous differentiation and specific antiproliferative effects in BRD4-dependent cell lines and patient-derived xenograft models. These data establish proof-of-concept for targeting protein-protein interactions of epigenetic 'readers', and provide a versatile chemical scaffold for the development of chemical probes more broadly throughout the bromodomain family.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature09504

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

1 retracted

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Regenass, U., & Lydon, N. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2558 · Cited by 273
Retracted
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652
Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
Huang, M., Ye, Y., Chen, S. R., Chai, J., Lu, J., Zhoa, L., Gu, L.-J., & Wang, Z.-Y. (1988) · Blood · doi:10.1182/blood.v72.2.567.567 · Cited by 2,445
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability
Niesen, F., Berglund, H., & Vedadi, M. (2007) · Nature Protocols · doi:10.1038/nprot.2007.321 · Cited by 2,420
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T. H., Bornmann, W. G., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,785
c-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
Recruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4
Yang, Z., Yik, J. H. N., Chen, R., He, N., Jang, M. K., Ozato, K., & Zhou, Q. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.029 · Cited by 1,141
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Bromodomain: an acetyl‐lysine binding domain
Zeng, L., & Zhou, M. (2002) · FEBS Letters · doi:10.1016/s0014-5793(01)03309-9 · Cited by 751

Flagged first, then by citations

Show all 42 references

2 of the 42 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Sueoka, H., Komatsu, H., Kobayashi, H. & Ehara, S. Thienotriazolodiazepine Compounds and Medicinal Uses Thereof 1–50 (Yoshitomi Pharmaceutical Industries, Ltd, 1998)

Sorted by citations

Items 601–700 of 1,029

The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer
Wilson, A. J., Stubbs, M. C., Liu, P., Ruggeri, B., & Khabele, D. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.03.049 · Cited by 116
Thiazolidinones: Synthesis, Reactivity, and Their Biological Applications
Nirwan, S., Chahal, V., & Kakkar, R. (2019) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.3514 · Cited by 116
Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy
Chelladurai, P., Boucherat, O., Stenmark, K. R., Kracht, M., Seeger, W., Bauer, U., Bonnet, S., & Pullamsetti, S. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14932 · Cited by 117
The role of the synovial fibroblast in rheumatoid arthritis pathogenesis
Turner, J. D., & Filer, A. D. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000148 · Cited by 115
BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire
Najafova, Z., Tirado-Magallanes, R., Subramaniam, M., Hossan, T., Schmídt, G., Nagarajan, S., Baumgart, S. J., Mishra, V. K., Bedi, U., Hesse, E., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw826 · Cited by 116
Self-citation
Bromodomain Histone Readers and Cancer
Jain, A. K., & Barton, M. C. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.11.020 · Cited by 116
Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial
Allen, C. E., Laetsch, T. W., Mody, R. J., Irwin, M. S., Lim, M. S., Adamson, P. C., Seibel, N. L., Parsons, D. W., Cho, Y., & Janeway, K. A. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw274 · Cited by 115
Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors
Ramakrishnan, G., Matta, H., Tolani, B., Triche, T. J., & Chaudhary, P. M. (2015) · Oncogene · doi:10.1038/onc.2015.245 · Cited by 114
BRD4 mediates NF-κB-dependent epithelial-mesenchymal transition and pulmonary fibrosis via transcriptional elongation
Tian, B., Zhao, Y., Sun, H., Zhang, Y., Yang, J., & Brasier, A. R. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00224.2016 · Cited by 114
Targeting HER2 Aberrations in Non–Small Cell Lung Cancer with Osimertinib
Liu, S., Li, S., Hai, J., Wang, X., Chen, T., Quinn, M. M., Gao, P., Zhang, Y., Ji, H., Cross, D. A. E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1875 · Cited by 114
p300 Acetyltransferase Regulates Androgen Receptor Degradation and PTEN-Deficient Prostate Tumorigenesis
Zhong, J., Ding, L., Bohrer, L. R., Pan, Y., Liu, P., Zhang, J., Sebo, T. J., Karnes, R. J., Tindall, D. J., van Deursen, J., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2485 · Cited by 114
7SK-BAF axis controls pervasive transcription at enhancers
Flynn, R. A., Do, B. T., Rubin, A. J., Calo, E., Lee, B., Kuchelmeister, H. Y., Rale, M. J., Chu, C., Kool, E. T., Wysocka, J., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3176 · Cited by 113
Tim-3 signaling in peripheral NK cells promotes maternal-fetal immune tolerance and alleviates pregnancy loss
Li, Y., Zhang, J., Zhang, D., Hong, X., Yu, T., Wang, S., Xu, Y., Piao, H., Yin, W., Yu, M., et al. (2017) · Science Signaling · doi:10.1126/scisignal.aah4323 · Cited by 113
The Functions of BET Proteins in Gene Transcription of Biology and Diseases
Cheung, K. L., Kim, C., & Zhou, M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.728777 · Cited by 115
4‐Acyl Pyrroles: Mimicking Acetylated Lysines in Histone Code Reading
Lucas, X., Wohlwend, D., Hügle, M. J., Schmidtkunz, K., Gerhardt, S., Schüle, R., Jung, M., Einsle, O., & Günther, S. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201307652 · Cited by 112
Bromodomain and extra-terminal (BET) family proteins: New therapeutic targets in major diseases
Padmanabhan, B., Mathur, S., Manjula, R., & Tripathi, S. K. (2016) · Journal of Biosciences · doi:10.1007/s12038-016-9600-6 · Cited by 112
Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma
Xu, L., Chen, Y., Mayakonda, A., Koh, L., Chong, Y. K., Buckley, D. L., Sandanaraj, E., Lim, S. W., Lin, R. Y., Ke, X., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1712363115 · Cited by 112
Self-citation
Inhibition of BRD4 suppresses the malignancy of breast cancer cells via regulation of Snail
Lu, L., Chen, Z., Lin, X., Tian, L., Su, Q., An, P., Li, W., Wu, Y., Du, J., Shan, H., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-019-0353-2 · Cited by 112
Development of BromoTag: A “Bump-and-Hole”–PROTAC System to Induce Potent, Rapid, and Selective Degradation of Tagged Target Proteins
Bond, A. G., Craigon, C., Chan, K.-H., Testa, A., Karapetsas, A., Fasimoye, R. Y., Macartney, T., Blow, J. J., Alessi, D. R., & Ciulli, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01532 · Cited by 116
Nested epistasis enhancer networks for robust genome regulation
Lin, X., Liu, Y., Liu, S., Zhu, X., Wu, L., Zhu, Y., Zhao, D., Xu, X., Chemparathy, A., Wang, H., et al. (2022) · Science · doi:10.1126/science.abk3512 · Cited by 112
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors
Xu, R., Zhao, Y., Liu, L., Bai, L., Yang, C., Zhou, B. N., Meagher, J. L., Chinnaswamy, K., Stuckey, J. A., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00613 · Cited by 112
Targeting the histone orthography of cancer: drugs for writers, erasers and readers
Simó‐Riudalbas, L., & Esteller, M. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12844 · Cited by 111
The BET Bromodomain Inhibitor I-BET151 Acts Downstream of Smoothened Protein to Abrogate the Growth of Hedgehog Protein-driven Cancers
Long, J., Li, B., Rodríguez‐Blanco, J., Pastori, C., Volmar, C., Wahlestedt, C., Capobianco, A. J., Bai, F., Pei, X., Ayad, N. G., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.595348 · Cited by 111
BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer
Wu, X., Liu, D., Tao, D., Xiang, W., Xiao, X., Wang, M., Wang, L., Luo, G., Li, Y., Zeng, F., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0750 · Cited by 111
Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies
Deng, C., Lipstein, M. R., Scotto, L., Serrano, X. O. J., Mangone, M. A., Li, S., Vendôme, J., Hao, Y., Xu, X., Deng, S., et al. (2016) · Blood · doi:10.1182/blood-2016-08-731240 · Cited by 111
A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets
Bayo, J., Fiore, E. J., Domínguez, L. M., Real, A., Malvicini, M., Rizzo, M., Atorrasagasti, C., García, M. G., Argemí, J., Martínez, E. D., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.007 · Cited by 111
Novel therapeutic strategies for multiple myeloma
Mimura, N., Hideshima, T., & Anderson, K. C. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.04.010 · Cited by 110
Synergistic effect of JQ 1 and rapamycin for treatment of human osteosarcoma
Lee, D. H., Qi, J., Bradner, J. E., SAID, J. W., Doan, N., Forscher, C. A., Yang, H. H., & Koeffler, H. P. (2014) · International Journal of Cancer · doi:10.1002/ijc.29269 · Cited by 110
Self-citation
Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib
Sun, B., Shah, B., Fiskus, W. C., Qi, J., Rajapakshe, K., Coarfa, C., Li, L., Devaraj, S. G. T., Sharma, S., Zhang, L., et al. (2015) · Blood · doi:10.1182/blood-2015-04-639542 · Cited by 110
Self-citation
Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B
Drouin, L., McGrath, S., Vidler, L. R., Chaikuad, A., Monteiro, O., Tallant, C., Philpott, M., Rogers, C. M., Fedorov, O., Liu, M., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501963e · Cited by 110
Self-citation
The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition
Sashida, G., Wang, C., Tomioka, T., Oshima, M., Aoyama, K., Kanai, A., Mochizuki‐Kashio, M., Harada, H., Shimoda, K., & Iwama, A. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151121 · Cited by 110
Spatially clustered loci with multiple enhancers are frequent targets of HIV-1 integration
Lucic, B., Chen, H., Kuzman, M., Zorita, E. V., Wegner, J., Minneker, V., Wang, W., Fronza, R., Laufs, S., Schmidt, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12046-3 · Cited by 111
CBP/p300: Critical Co-Activators for Nuclear Steroid Hormone Receptors and Emerging Therapeutic Targets in Prostate and Breast Cancers
Waddell, A. R., Huang, H., & Liao, D. (2021) · Cancers · doi:10.3390/cancers13122872 · Cited by 110
Tracking chromatin state changes using nanoscale photo-proximity labelling
Seath, C. P., Burton, A. J., Sun, X., Lee, G., Kleiner, R. E., MacMillan, D. W. C., & Muir, T. W. (2023) · Nature · doi:10.1038/s41586-023-05914-y · Cited by 115
Epigenetic regulators in cancer therapy and progression
Marei, H. E. S. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01003-7 · Cited by 116
The Role of BPTF in Melanoma Progression and in Response to BRAF-Targeted Therapy
Dar, A. A., Nosrati, M., Bezrookove, V., de Semir, D., Majid, S., Thummala, S., Sun, V., Tong, S., Leong, S. P. L., Minor, D. R., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv034 · Cited by 110
MYC: Master Regulator of Immune Privilege
Casey, S. C., Baylot, V., & Felsher, D. W. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.01.002 · Cited by 109
ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors
Berns, K., Caumanns, J. J., Hijmans, E. M., Gennissen, A. M. C., Severson, T., Evers, B., Wisman, G. B. A., Meersma, G. J., Lieftink, C., Beijersbergen, R. L., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0300-6 · Cited by 109
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Li, W., Gupta, S. K., Han, W., Kundson, R. A., Nelson, S., Knutson, D. L., Greipp, P. T., Elsawa, S. F., Sotomayor, E. M., & Gupta, M. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0761-2 · Cited by 109
Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases
Kulikowski, E., Rakai, B. D., & Wong, N. C. W. (2020) · Medicinal Research Reviews · doi:10.1002/med.21730 · Cited by 109
Clinical advances in targeting epigenetics for cancer therapy
Feng, S., & Carvalho, D. D. D. (2021) · FEBS Journal · doi:10.1111/febs.15750 · Cited by 109
Now open: Evolving insights to the roles of lysine acetylation in chromatin organization and function
Chen, Y.-J. C., Koutelou, E., & Dent, S. (2022) · Molecular Cell · doi:10.1016/j.molcel.2021.12.004 · Cited by 110
Brd4 Is Essential for IL-1β-Induced Inflammation in Human Airway Epithelial Cells
Khan, Y. M., Kirkham, P., Barnes, P. J., & Adcock, I. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095051 · Cited by 108
Discovery of Chemical Inhibitors of Human Bromodomains
Zhang, G., Smith, S. G., & Zhou, M. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00205 · Cited by 108
Strategically targeting MYC in cancer
Posternak, V., & Cole, M. D. (2016) · F1000Research · doi:10.12688/f1000research.7879.1 · Cited by 108
Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia
Picaud, S., Leonards, K., Lambert, J., Dovey, O. M., Wells, C. D., Fedorov, O., Monteiro, O., Fujisawa, T., Wang, C., Lingard, H., et al. (2016) · Science Advances · doi:10.1126/sciadv.1600760 · Cited by 109
Self-citation
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity
Postel-Vinay, S. C., Herbschleb, K. H., Massard, C., Woodcock, V. K., Soria, J., Walter, A. O., Ewerton, F., Poelman, M., Benson, N., Ocker, M., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.020 · Cited by 108
Blocking an N-terminal acetylation–dependent protein interaction inhibits an E3 ligase
Scott, D. C., Hammill, J. T., Min, J., Rhee, D. Y., Connelly, M., Sviderskiy, V. O., Bhasin, D., Chen, Y., Ong, S. S., Chai, S. C., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2386 · Cited by 108
Targeting GLI factors to inhibit the Hedgehog pathway
Infante, P., Alfonsi, R., Botta, B., Mori, M., & Marcotullio, L. D. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.05.006 · Cited by 107
Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors
Gehling, V. S., Hewitt, M. C., Vaswani, R. G., Leblanc, Y., Côté, A., Nasveschuk, C. G., Taylor, A. M., Harmange, J.-C., Audia, J. E., Pardo, E., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4001485 · Cited by 107
Roles of the Hedgehog Signaling Pathway in Epidermal and Hair Follicle Development, Homeostasis, and Cancer
Abe, Y., & Tanaka, N. (2017) · Journal of Developmental Biology · doi:10.3390/jdb5040012 · Cited by 111
Functions of BET proteins in erythroid gene expression
Stonestrom, A. J., Hsu, S. C., Jahn, K. S., Huang, P., Keller, C. A., Giardine, B. M., Kadauke, S., Campbell, A. E., Evans, P., Hardison, R. C., et al. (2015) · Blood · doi:10.1182/blood-2014-10-607309 · Cited by 107
An epigenetic gateway to brain tumor cell identity
Mack, S. C., Hubert, C. G., Miller, T. E., Taylor, M. D., & Rich, J. N. (2015) · Nature Neuroscience · doi:10.1038/nn.4190 · Cited by 106
C/EBPα creates elite cells for iPSC reprogramming by upregulating Klf4 and increasing the levels of Lsd1 and Brd4
Stefano, B. D., Collombet, S., Jakobsen, J. S., Wierer, M., Sardina, J. L., Lackner, A., Stadhouders, R., Segura-Morales, C., Francesconi, M., Limone, F., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3326 · Cited by 106
Discovery of a Small-Molecule Bromodomain-Containing Protein 4 (BRD4) Inhibitor That Induces AMP-Activated Protein Kinase-Modulated Autophagy-Associated Cell Death in Breast Cancer
Ouyang, L., Zhang, L., Liu, J., Fu, L., Yao, D., Zhao, Y., Zhang, S., Wang, G., He, G., & Liu, B. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00275 · Cited by 106
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Noblejas‐López, M. D. M., Nieto‐Jiménez, C., Burgos, M., Sango, M. G., Montero, J. C., Esparı́s-Ogando, A., Pandiella, A., Galán‐Moya, E. M., & Ocaña, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1387-5 · Cited by 106
Discovery of Orally Bioavailable Chromone Derivatives as Potent and Selective BRD4 Inhibitors: Scaffold Hopping, Optimization, and Pharmacological Evaluation
Liu, Z., Chen, H., Wang, P., Li, Y., Wold, E. A., Leonard, P. G., Joseph, S., Brasier, A. R., Tian, B., & Zhou, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00035 · Cited by 106
Regulation of angiotensin II actions by enhancers and super-enhancers in vascular smooth muscle cells
Das, S., Senapati, P., Chen, Z., Reddy, M. A., Ganguly, R., Lanting, L. L., Mandi, V., Bansal, A., Leung, A., Zhang, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01629-7 · Cited by 105
BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2/NID1 signaling
Zhou, S., Zhang, S., Wang, L., Huang, S., Yuan, Y., Yang, J., Wang, H., Li, X., Wang, P., Zhou, L., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-0218-z · Cited by 105
iPPI-DB: a manually curated and interactive database of small non-peptide inhibitors of protein–protein interactions
Labbé, C. M., Laconde, G., Kuenemann, M. A., Villoutreix, B. O., & Sperandio, O. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.05.003 · Cited by 104
Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation
Liu, Z., Tian, B., Chen, H., Wang, P., Brasier, A. R., & Zhou, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.04.006 · Cited by 104
BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras -Mutant Non–Small Cell Lung Cancer
Adeegbe, D. O., Liu, S., Hattersley, M. M., Bowden, M., Zhou, C. W., Li, S., Vlahos, R., Grondine, M. R., Dolgalev, I., Ivanova, E. V., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0077 · Cited by 104
Self-citation
The diverse roles of SPOP in prostate cancer and kidney cancer
Wang, Z. P., Song, Y., Ye, M., Dai, X., Zhu, X., & Wei, W. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0314-z · Cited by 104
BRD4-directed super-enhancer organization of transcription repression programs links to chemotherapeutic efficacy in breast cancer
Liu, B., Liu, X., Han, L., Chen, X., Wu, X., Wu, J., Yan, D., Wang, Y., Liu, S., Shan, L., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2109133119 · Cited by 104
Self-citation
Small molecules targeting microRNA for cancer therapy: Promises and obstacles
Wen, D., Danquah, M. K., Chaudhary, A., & Mahato, R. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.011 · Cited by 104
JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer*
Qiu, H., Jackson, A. L., Kilgore, J. E., Zhong, Y., Chan, L. L.-Y., Gehrig, P. A., Zhou, C., & Bae-Jump, V. L. (2015) · Oncotarget · doi:10.18632/oncotarget.3126 · Cited by 103
Retracted
Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors
Tolani, B., Ramakrishnan, G., Punj, V., Matta, H., & Chaudhary, P. M. (2013) · Oncogene · doi:10.1038/onc.2013.242 · Cited by 103
Chromodomain Antagonists That Target the Polycomb-Group Methyllysine Reader Protein Chromobox Homolog 7 (CBX7)
Simhadri, C., Daze, K. D., Douglas, S. F., Quon, T. T. H., Dev, A., Gignac, M. C., Peng, F., Heller, M., Boulanger, M. J., Wulff, J. E., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401487x · Cited by 103
Targeting BET bromodomain proteins in solid tumors
Sahai, V., Redig, A. J., Collier, K. A., Eckerdt, F., & Munshi, H. G. (2016) · Oncotarget · doi:10.18632/oncotarget.9804 · Cited by 103
Bromodomain and Extraterminal Proteins as Novel Epigenetic Targets for Renal Diseases
Morgado‐Pascual, J. L., Rayego‐Mateos, S., Tejedor-Santamaria, L., Suárez-Álvarez, B., & Ruiz‐Ortega, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01315 · Cited by 103
FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials
Mohanty, A. R., Pharaon, R. R., Nam, A., Salgia, S. K., Kulkarni, P., & Massarelli, E. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1740680 · Cited by 103
Real-Time Imaging of Histone H4K12–Specific Acetylation Determines the Modes of Action of Histone Deacetylase and Bromodomain Inhibitors
Ito, T., Umehara, T., Sasaki, K., Nakamura, Y., Nishino, N., Terada, T., Shirouzu, M., Padmanabhan, B., Yokoyama, S., Ito, A., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.02.009 · Cited by 103
BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1
Zhang, Z., Ma, P., Jing, Y., Yan, Y., Cai, M., Zhang, M., Zhang, S., Peng, H., Ji, Z., Di, W. J., et al. (2015) · Theranostics · doi:10.7150/thno.13178 · Cited by 103
Multiple P-TEFbs cooperatively regulate the release of promoter-proximally paused RNA polymerase II
Lü, X., Zhu, X., Li, Y., Liu, M., Yu, B., Wang, Y., Rao, M., Yang, H., Zhou, K., Wang, Y., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw571 · Cited by 103
Self-citation
RapidCaP, a Novel GEM Model for Metastatic Prostate Cancer Analysis and Therapy, Reveals Myc as a Driver of Pten -Mutant Metastasis
Cho, H., Herzka, T. M., Wu, Z., Qi, J., Wilkinson, J. E., Bradner, J. E., Robinson, B. D., Castillo-Martín, M., Cordon‐Cardo, C., & Trotman, L. C. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0346 · Cited by 102
Self-citation
Inhibition of BRD4 attenuates transverse aortic constriction- and TGF-β-induced endothelial-mesenchymal transition and cardiac fibrosis
Song, S., Liu, L., Yu, Y., Zhang, R., Li, Y., Cao, W., Xiao, Y., Fang, G., Li, Z., Wang, X., et al. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.12.002 · Cited by 102
Discovery of a selective inhibitor of doublecortin like kinase 1
Ferguson, F. M., Nabet, B., Raghavan, S., Liu, Y., Leggett, A. L., Kuljanin, M., Kalekar, R. L., Yang, A., He, S., Wang, J., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0506-0 · Cited by 102
From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases
Landmesser, U., Poller, W. C., Tsimikas, S., Most, P., Paneni, F., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa229 · Cited by 102
BRD4 inhibition by JQ1 prevents high-fat diet-induced diabetic cardiomyopathy by activating PINK1/Parkin-mediated mitophagy in vivo
Mu, J., Zhang, D., Tian, Y., Xie, Z., & Zou, M. (2020) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2020.09.003 · Cited by 102
Alternative modulation of protein–protein interactions by small molecules
Fischer, G., Rossmann, M., & Hyvönen, M. (2015) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2015.04.006 · Cited by 102
BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications
To, K. K. W., Xing, E., Larue, R. C., & Li, P. (2023) · Molecules · doi:10.3390/molecules28073043 · Cited by 103
Multivalent Histone and DNA Engagement by a PHD/BRD/PWWP Triple Reader Cassette Recruits ZMYND8 to K14ac-Rich Chromatin
Savitsky, P. A., Krojer, T. J., Fujisawa, T., Lambert, J., Picaud, S., Wang, C. Y., Shanle, E. K., Krajewski, K., Friedrichsen, H. J., Kanapin, A. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.014 · Cited by 102
Self-citation
Chromatin Reader Brd4 Functions in Ig Class Switching as a Repair Complex Adaptor of Nonhomologous End-Joining
Stanlie, A., Yousif, A. S., Akiyama, H., Honjo, T., & Begum, N. A. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.018 · Cited by 101
Targeting Low-Druggability Bromodomains: Fragment Based Screening and Inhibitor Design against the BAZ2B Bromodomain
Ferguson, F. M., Fedorov, O., Chaikuad, A., Philpott, M., Muniz, J. R. C., Felletár, I., von Delft, F., Heightman, T. D., Knapp, S., Abell, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401582c · Cited by 101
Self-citation
Drug and disease signature integration identifies synergistic combinations in glioblastoma
Stathias, V., Jermakowicz, A. M., Maloof, M. E., Forlin, M., Walters, W. M., Suter, R. K., Durante, M. A., Williams, S. L., Harbour, J. W., Volmar, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07659-z · Cited by 101
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
Ge, J. Y., Shu, S., Kwon, M., Jovanović, B., Murphy, K. C., Gulvady, A. C., Fassl, A., Trinh, A. C., Kuang, Y., Heavey, G. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16170-3 · Cited by 102
Self-citation
BRD4 Couples NF-κB/RelA with Airway Inflammation and the IRF-RIG-I Amplification Loop in Respiratory Syncytial Virus Infection
Tian, B., Yang, J., Zhao, Y., Ivanciuc, T., Sun, H., Garofalo, R. P., & Brasier, A. R. (2017) · Journal of Virology · doi:10.1128/jvi.00007-17 · Cited by 101
Unravelling the genomic targets of small molecules using high-throughput sequencing
Rodriguez, R., & Miller, K. M. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3796 · Cited by 100
Inhibition of Super-Enhancer Activity in Autoinflammatory Site-Derived T Cells Reduces Disease-Associated Gene Expression
Peeters, J. G. C., Vervoort, S. J., Tan, S., Mijnheer, G., de Roock, S., Vastert, S. J., Nieuwenhuis, E. E. S., van Wijk, F., Prakken, B. J., Creyghton, M. P., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.046 · Cited by 100
Differential cofactor dependencies define distinct types of human enhancers
Neumayr, C., Haberle, V., Serebreni, L., Karner, K., Hendy, O., Boija, A., Henninger, J. E., Li, C. H., Stejskal, K., Lin, G., et al. (2022) · Nature · doi:10.1038/s41586-022-04779-x · Cited by 100
Malignant genome reprogramming by ATAD2
Boussouar, F., Jamshidikia, M., Morozumi, Y., Rousseaux, S., & Khochbin, S. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2013.06.003 · Cited by 100
Discovery of a Potent, Cell Penetrant, and Selective p300/CBP-Associated Factor (PCAF)/General Control Nonderepressible 5 (GCN5) Bromodomain Chemical Probe
Humphreys, P. G., Bamborough, P., Chung, C., Craggs, P. D., Gordon, L. J., Grandi, P., Hayhow, T. G., Hussain, J., Jones, K. L., Lindon, M. J., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01566 · Cited by 100
SMYD2-Mediated Histone Methylation Contributes to HIV-1 Latency
Boehm, D., Jeng, M. Y., Camus, G., Gramatica, A., Schwarzer, R., Johnson, J. R., Hull, P. A., Montaño, M., Sakane, N., Pagans, S., et al. (2017) · Cell Host & Microbe · doi:10.1016/j.chom.2017.04.011 · Cited by 100
[1,2,4]Triazolo[4,3-a]phthalazines: Inhibitors of Diverse Bromodomains
Fedorov, O., Lingard, H., Wells, C. D., Monteiro, O., Picaud, S., Keates, T., Yapp, C., Philpott, M., Martin, S. J., Felletár, I., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm401568s · Cited by 99
Self-citation
ERK5 kinase activity is dispensable for cellular immune response and proliferation
Lin, E. C. K., Amantea, C. M., Nomanbhoy, T. K., Weissig, H., Ishiyama, J., Hu, Y., Sidique, S., Li, B., Kozarich, J. W., & Rosenblum, J. S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609019113 · Cited by 99
Haploinsufficiency of the Chromatin Remodeler BPTF Causes Syndromic Developmental and Speech Delay, Postnatal Microcephaly, and Dysmorphic Features
Stankiewicz, P., Khan, T. N., Szafrański, P., Slattery, L., Streff, H. E., Vetrini, F., Bernstein, J. A., Brown, C., Rosenfeld, J. A., Rednam, S. P., et al. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.08.014 · Cited by 99
BET Inhibition Overcomes Receptor Tyrosine Kinase–Mediated Cetuximab Resistance in HNSCC
Leonard, B. C., Brand, T. M., O’Keefe, R. A., Lee, E. D., Zeng, Y., Kemmer, J. D., Li, H., Grandis, J. R., & Bhola, N. E. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0459 · Cited by 99
Investigating crosstalk between H3K27 acetylation and H3K4 trimethylation in CRISPR/dCas-based epigenome editing and gene activation
Zhao, W., Xu, Y., Wang, Y., Gao, D., King, J. J., Xu, Y., & Liang, F. (2021) · Scientific Reports · doi:10.1038/s41598-021-95398-5 · Cited by 99
Self-citation
Identification and Characterization of Small Molecule Inhibitors of a Plant Homeodomain Finger
Wagner, E. K., Nath, N., Flemming, R., Feltenberger, J. B., & Denu, J. M. (2012) · Biochemistry · doi:10.1021/bi3009278 · Cited by 99
The methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophyPreprint
Proserpio, V., Fittipaldi, R., Ryall, J. G., Sartorelli, V., & Caretti, G. (2013) · Genes & Development · doi:10.1101/gad.217240.113 · Cited by 99

Authors: Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., Philpott, M., Munro, S., McKeown, M. R., Wang, Y., Christie, A. L., West, N., Cameron, M. J., Schwartz, B., Heightman, T. D., La Thangue, N., French, C. A., Wiest, O., Kung, A. L., Knapp, S., & Bradner, J. E.
Affiliations: University of Oxford (GB)
Harvard University (US)
University of Notre Dame (US)
Brigham and Women's Hospital (US)
Boston Children's Hospital (US)
Corresponding author: Knapp, Stefan
Bradner, James E.
ORCID: Filippakopoulos, Panagis
Qi, Jun
Picaud, Sarah
Shen, Yao
Fedorov, Oleg
Hickman, Tyler T.
Philpott, Martin
Munro, Shonagh
McKeown, Michael R.
Wang, Yuchuan
Schwartz, Brian
Heightman, Tom D.
French, Christopher A.
Wiest, Olaf
Kung, Andrew L.
Knapp, Stefan
Bradner, James E.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2010-09-24
Volume: 468
Issue: 7327
Pages: 1067-1073
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature09504
PMC: PMC3010259
OpenAlex: W2041535798
Cited by: 4,262
References: 42
Citations by year: 2026: 217 · 2025: 307 · 2024: 304 · 2023: 307 · 2022: 309 · 2021: 323 · 2020: 340 · 2019: 323 · 2018: 303 · 2017: 306 · 2016: 334 · 2015: 279 · 2014: 246 · 2013: 177 · 2012: 117
FWCI: 48.89
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Oxford University Research Archive (ORA) (University of Oxford) (submittedVersion)
Funders: Wellcome Trust
Cancer Research UK (13058)
U.S. Public Health Service (T32-075762)
Canadian Institutes of Health Research
National Cancer Institute (K08CA128972)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords: BET inhibitors, JQ1, BRD4, epigenetic reader protein, protein-protein interaction inhibition, squamous cell carcinoma, histone acetylation, co-crystal structure, chemical probes, transcriptional regulation
MeSH terms: Bromodomain Containing Proteins, Amino Acid Sequence, Animals, Azirines, Binding Sites, Carcinoma, Squamous Cell, Cell Differentiation, Chromatin, Dihydropyridines, Female, Humans, Mice, Nude, Models, Molecular, Molecular Sequence Data, Nuclear Proteins, Protein Binding, Recombinant Proteins, Skin Neoplasms, Stereoisomerism, Transcription Factors, Sequence Alignment, Protein Structure, Tertiary, Cell Cycle Proteins, Cell Line, Tumor, Cell Proliferation, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Selective inhibition of BET bromodomains

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks